SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.
SciNeuro has raised $53.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2025.
SciNeuro's investors include HSG, General Atlantic, ARCH Venture Partners, Lilly Asia Ventures, Boyu Capital.
SciNeuro is headquartered in Rockville, United States.
SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.
SciNeuro is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SciNeuro — Funding & Investors." VCBacked, December 4, 2025, https://www.vcbacked.co/company/scineuro. Accessed July 19, 2026.
VCBacked. (2025). SciNeuro — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/scineuro
{{cite web |title=SciNeuro — Funding & Investors |url=https://www.vcbacked.co/company/scineuro |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated